Health outcomes of schizophrenia in Thailand: Health care provider and patient perspectives

Asian Journal of Psychiatry

Volumn 3, Issue 4, 2010, Pages 200-205

  Phanthunane, Pudtan ^a,b,d   Vos, Theo ^a,b   Whiteford, Harvey ^b,c   Bertram, Melanie ^a,b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Queensland Centre for Mental Health Research   (Australia)

^d NARESUAN UNIVERSITY   (Thailand)

Author keywords

Disability; Outcome; Psychosis; Schizophrenia; Severity

Indexed keywords

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; THAILAND;

EID: 78649813459     PISSN: 18762018     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajp.2010.09.004     Document Type: Article

References (45)

1. Almond S., Knapp M., Francois C., Toumi M., Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br. J. Psychiatr. 2004, 184(4):346-351.
2. Bagnall A.-M., Jones L., Ginnelly L., Lewis R., Glanville J., Gilbody S., et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol. Assess. 2003, 7(13):1-6.
3. Barbato A. Schizophrenia and Public Health 1998, World Health Organization, Geneva.
4. Burns T. Evolution of outcome measures in schizophrenia. Br. J. Psychiatr. 2007, 191(50):1-6.
5. Castle D., Copolov D., Wykes T. Pharmacological and Psychosocial Treatments in Schizophrenia 2003, Matin Dunitz Ltd., London. 2nd ed.
6. Cohen A., Patel V., Thara R., Gureje O. Questioning an axiom: better prognosis for schizophrenia in the developing world?. Schizophr. Bull. 2008, 34(2):229-244.
7. Dingemans P.M.A.J., Linszen D.H., Lenior M.E., Smeets R.M.W. Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E). Psychopharmacology 1995, 122(3):263-267.
8. Docherty J.P., Bossie C.A., Lachaux B., Bouhours P., Zhu Y., Lasser R., Gharabawi G.M. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int. Clin. Psychopharmacol. 2007, 22(1):51-55.
9. Donaldson G. Patient-reported outcomes and the mandate of measurement. Qual. Life Res. 2008, 17(10):1303-1313.
10. Donaldson G.W., Moinpour C.M. Individual differences in quality-of-life treatment response. Med. Care 2002, 40(6 Suppl.):III39-III53.
11. Eack S.M., Newhill C.E. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr. Bull. 2007, 33(5):1225-1237.
12. A Standardised Instrument for use as a Measure of Health Outcome 2008, EuroQoL Group, EuroQoL Group, Rotterdam, [cited 2008 May 13]; Available from: http://www.euroqol.org/eq-5d/what-is-eq-5d.html.
13. Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. Relationships between changes in symptom ratings, neuropsychological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatr. Res. 1997, 72(3):161-166.
14. Gee L., Pearce E., Jackson M. Quality of life in schizophrenia: a grounded theory approach. Health Qual. Life Outcomes 2003, 1(1):31.
15. Gureje O., Herrman H., Harvey C., Trauer T., Jablensky A. Defining disability in psychosis: performance of the diagnostic interview for psychosis-disability module (DIP-DIS) in the Australian National Survey of Psychotic Disorders. Aust. N. Z. J. Psychiatr. 2001, 35(6):846-851.
16. Haro J.M., Kamath S.A., Ochoa S., et al. The Clinical Global Impression Schizophrenia Scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr. Scand. 2003, 107:16-23.
17. Hoeymans N., van Lindert H., Westert G.P. The health status of the Dutch population as assessed by the EQ-6D. Qual. Life Res. 2005, 14(3):655-663.
18. Hopper K., Harrison G., Janca A., Sartorius N. Recovery from Schizophrenia: An International Perspective 2007, Oxford University, New York.
19. Hunter R., Cameron R., Norrie J. Using patient-reported outcomes in schizophrenia: the Scottish Schizophrenia Outcomes study. Psychiatr. Serv. 2009, 60(2):240-245.
20. International Health Policy Program Burden of Disease and Injuries in Thailand in 2004 2008, International Health Policy Program, Bangkok, [cited 2008 Nov 15]; Available from: http://thaibod.org/.
21. Israel G.D. Determining Sample Size 2008, University of Florida, [cited 2008 May 9]; Available from: http://edis.ifas.ufl.edu/PD006.
22. Joseph V., Keith H.N., Kenneth L.S., Daniel G., Elizabeth A.G. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatr. Res. 2000, 97(2):129-135.
23. Königa H.-H., Roick C., Angermeyer M.C. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur. Psychiatr. 2007, 22(3):177-187.
24. Kurtz M.M. Symptoms versus neurocognitive skills as correlates of everyday functioning in severe mental illness. Expert Rev. Neurother. 2006, 6(1):47-56.
25. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E.V.A., Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. Br. J. Psychiatr. 2005, 187(4):366-371.
26. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
27. Mathers C., Vos T., Stevenson C. The Burden of Disease and Injury in Australia 1999, Australian Institute of Health and Welfare, Canberra.
28. McCabe R., Saidi M., Priebe S. Patient-reported outcomes in schizophrenia. Br. J. Psychiatr. 2007, 191(50):21-28.
29. Montes J.M., Ciudad A., Gascon J., Gomez J.C. Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study. Prog. Neuropsychopharmacol. Biol. Psychiatr. 2003, 27(4):667.
30. Murray C.J.L., Lopez A.D. The Global Burden of Disease 1996, The Harvard School of Public Health, Boston.
31. Narvaez J.M., Twamley E.W., McKibbin C.L., Heaton R.K., Patterson T.L. Subjective and objective quality of life in schizophrenia. Schizophr. Res. 2008, 98(1-3):201-208.
32. Phanthunane P., Chaipornsupaisan W., Vos T. A Survey of Severity, Quality of Life and Current Treatment Patterns in People with Schizophrenia in Thailand 2008, SPICE Project, Nonthaburi.
33. Prieto L., Sacristán J.A., Hormaechea J.A., Casado A., Badia X., Gómez J.C. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr. Med. Res. Opin. 2004, 20(6):827-835.
34. Ross M.G.N., Ashok K.M., Terry M., et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 2000, 102(4):303-309.
35. Sakthong P. Health-related quality of life. Thai Pharm. Health Sci. J. 2007, 2(3):327-337.
36. Sapin C., Fantino B., Nowicki M.-L., Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual. Life Outcomes 2004, 2(20):1-8.
37. Savilla K., Kettler L., Galletly C. Relationships between cognitive deficits, symptoms and quality of life in schizophrenia. Aust. N. Z. J. Psychiatr. 2008, 42(6):496-504.
38. Shumway M. Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups. Schizophr. Bull. 2003, 29(2):257-266.
39. Sirwanarangsun P. Prevalence of mental disorders in Thailand: a national survey 2003. J. Psychiatr. Assoc. Thai. 2004, 12(3):178.
40. Stouthard M.E., Essink-Bot M.-L., Bonsel G.J., Barendregt J.J., Kramer P.G.N., van de Water H.P.A., et al. Disability Weights for Diseases in the Netherland 1997, Department of Public Health, Erasmus University Rotterdam, Rotterdam.
41. Velligan D.I., Alphs L.D. Negative symptoms in schizophrenia: the importance of identification and treatment. Psychiatric Times 2008, [cited 25 3]; Available from: http://www.psychiatrictimes.com/schizophrenia/content/article/10168/1147581.
42. Ventura J., Green M.F., Shaner A., Liberman R.P. Training and quality assurance with the Brief Psychiatric Rating Scale: 'The drift busters'. Int. J. Methods Psychiatr. Res. 1993, 3:221-224.
43. Whiteford H., Teesson M., Scheurer R., Jamison D. Responding to the Burden of Mental Illness 2001, World Health Organization, Los Angeles, [updated July cited 2007 January 1]; Available from: http://www.whoindia.org/LinkFiles/Commision_on_Macroeconomic_and_Health_01_12.pdf.
44. Whiteford H.A., Peabody C.A. The differential diagnosis of negative symptoms in chronic schizophrenia. Aust. N. Z. J. Psychiatr. 1989, 23(4):491-496.
45. Xiang Y.-T., Weng Y.-Z., Leung C.-M., Tang W.-K., Ungvari G.S. Quality of life of Chinese schizophrenia outpatients in Hong Kong: relationship to sociodemographic factors and symptomatology. Aust. N. Z. J. Psychiatr. 2007, 41(5):442-449.